In This Article:
As global markets faced significant volatility in August 2024, the rotation toward value stocks and small-caps saw a notable pullback, reflecting broader economic concerns. Despite these challenges, discerning investors continue to seek opportunities within the small-cap sector, particularly those with insider action that may signal potential undervaluation. In this environment, identifying good stocks often involves looking for companies with strong fundamentals and insider buying activity, which can indicate confidence in the company's future prospects.
Top 10 Undervalued Small Caps With Insider Buying
Name | PE | PS | Discount to Fair Value | Value Rating |
---|---|---|---|---|
Nexus Industrial REIT | 2.6x | 3.3x | 24.76% | ★★★★★☆ |
Chatham Lodging Trust | NA | 1.3x | 29.45% | ★★★★★☆ |
Citizens & Northern | 12.4x | 2.8x | 46.00% | ★★★★☆☆ |
Guardian Capital Group | 10.5x | 4.1x | 37.94% | ★★★★☆☆ |
Calfrac Well Services | 2.7x | 0.2x | -118.24% | ★★★★☆☆ |
Hemisphere Energy | 6.8x | 2.5x | 14.13% | ★★★☆☆☆ |
NSI | NA | 4.5x | 45.59% | ★★★☆☆☆ |
Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
Alta Equipment Group | NA | 0.2x | -158.61% | ★★★☆☆☆ |
Delek US Holdings | NA | 0.1x | -108.57% | ★★★☆☆☆ |
Here we highlight a subset of our preferred stocks from the screener.
Assura
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Assura is a UK-based real estate investment trust specializing in the development and management of primary care properties, with a market cap of approximately £2.22 billion.
Operations: Assura generates revenue primarily from its core segment, with the latest figure being £157.8 million. The company has experienced fluctuations in net income margins, with recent periods showing negative values. Gross profit margin was 90.81% as of March 2024, reflecting a downward trend over time from earlier higher levels such as 95.75% in September 2016. Operating expenses and general & administrative expenses have shown slight increases over the years, impacting overall profitability.
PE: -44.0x
Assura, a healthcare property investor and developer, recently entered a £250 million joint venture with the Universities Superannuation Scheme to support NHS infrastructure. This partnership aims for significant growth, potentially reaching £400 million. Despite reporting a net loss of £28.8 million for the year ending March 2024, insider confidence has been evident with recent share purchases in June 2024. The company’s strategic moves and earnings forecast of 40.91% annual growth highlight its potential within its sector.
-
Click here and access our complete valuation analysis report to understand the dynamics of Assura.
-
Review our historical performance report to gain insights into Assura's's past performance.